GLP-1 Receptor Agonists in Patients with Hepatic Adenoma

Contraindications and Safety Profile

The American College of Cardiology recommends that GLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma due to thyroid C-cell tumor risk observed in rodent studies 1, 2
The American College of Cardiology states that multiple endocrine neoplasia syndrome type 2 (MEN2) is an absolute contraindication for GLP-1 receptor agonists due to thyroid-related concerns 1, 2, 3
The American College of Cardiology notes that severe renal impairment or end-stage renal disease is a contraindication for certain GLP-1 receptor agonists (exenatide, lixisenatide), while liraglutide and semaglutide can be used with caution in this population 1, 2

Liraglutide improved liver histology in patients with biopsy-proven NASH, delaying progression of fibrosis in a randomized controlled trial, as reported in Diabetes Care 4
Semaglutide achieved resolution of steatohepatitis in 59% of patients (versus 17% with placebo) and significantly slowed progression of liver fibrosis over 72 weeks, according to Diabetes Care 4
GLP-1 receptor agonists reduce hepatic steatosis and improve liver enzymes (AST, ALT) in patients with type 2 diabetes and NAFLD, as stated in Diabetes Care 4

The American College of Cardiology advises caution when using GLP-1 receptor agonists in patients with active gallbladder disease, as they may increase the risk of gallbladder disease including acute cholecystitis 1, 5
The American College of Cardiology recommends using liraglutide and semaglutide with caution in patients with a history of pancreatitis, although the FDA and European Medicines Agency have not identified a causal link 1, 2, 3

The American College of Cardiology suggests starting with low doses and titrating gradually to minimize gastrointestinal side effects (nausea, vomiting, diarrhea) when prescribing GLP-1 receptor agonists 1, 5, 3
The American College of Cardiology recommends monitoring for gallbladder symptoms given the increased risk of cholecystitis with this drug class 1, 5
The American College of Cardiology advises reducing insulin or sulfonylurea doses by approximately 20% when initiating GLP-1 receptor agonists to prevent hypoglycemia 5, 2, 6
The American College of Cardiology suggests considering cardiovascular benefits, prioritizing agents with proven cardiovascular benefit (liraglutide, semaglutide, dulaglutide) in patients with established atherosclerotic disease 1, 5, 6